Chao-Yang Liang

Chao-Yang Liang

Auto-generated profile, based on publicly available information

Chao-Yang Liang

Department of Thoracic Surgery The First Medical Center of Chinese PLA General Hospital Beijing People's Republic of China

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2014 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
JGJuntang Guo
Juntang Guo
XCXiangyang Chu
Xiangyang Chu
YLYang Liu
Yang Liu
NZNaikang Zhou
Naikang Zhou
YMYongfu Ma
Yongfu Ma
CLChaoyang Liang
Chaoyang Liang
The aim of this study was to analyze our experience with management of intrathoracic anastomotic leak after esophagectomy.

1 October 2011
Verified
Journal Article
Closed access
WSWei-An Song
Wei-An Song
XLXi Liu
Xi Liu
XTXiao-Dong Tian
Xiao-Dong Tian
WWWei Wang
Wei Wang
CLChao-Yang Liang
Chao-Yang Liang
NZNai-Kang Zhou
Nai-Kang Zhou

9 August 2023 in Cancer Medicine
Verified
Journal Article
Open access
LSleilei shen
leilei shen
JGJuntang Guo
Juntang Guo
WZWeidong Zhang
Weidong Zhang
LZLianbin Zhang
Lianbin Zhang
XLXi Liu
Xi Liu
YLYang Liu
Yang Liu
Background: Adjuvant therapy for stage IB non‐small cell lung cancer remains debatable. In this real‐world study, we evaluate the efficacy and safety of adjuvant epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) for resected stage IB lung adenocarcinoma.Methods: This real‐world study recruited 249 patients diagnosed with stage IB disease after surgical resection between January 2013 and September 2021. Sixty‐six (26.5%) patients received adjuvant targeted therapy (TKIs group), and 183 (73.5%) were enrolled in the clinical observation (CO) group. Propensity scores were matched to minimize the observed confounder effects between the two groups, and 59 patient pairs were matched. The primary endpoint was disease‐free survival (DFS).Results: In the TKI group, 38 (64.4%) patients chose to receive icotinib, 27.1% (16/59) received gefitinib, and 5 patients (8.5%) chose osimertinib. The median follow‐up time was 30.8 months (range: 7–107 months). Two (3.4%) patients in the TKI group and 10 (16.9%) in the CO group experienced disease relapse. The 3‐year DFS rates were 98.3% in the TKI group and 83.0% in the CO group (HR: 0.10; 95% CI: 0.01–0.78; p = 0.008). DFS differences were found in the entire cohort (p = 0.005) and the matched cohort (p = 0.024) between the two groups. Multivariate analysis showed that adjuvant EGFR‐TKIs was an independent factor for DFS (HR: 0.211; 95% CI: 0.045–0.979; p = 0.047), along with poor cell differentiation (HR: 5.256; 95% CI: 1.648–16.769; p = 0.005), and spread through air spaces (HR: 5.612; 95% CI: 1.137–27.700; p = 0.034). None of the patients discontinued EGFR‐TKIs owing to the low occurrence rate of treatment‐related serious adverse events.Conclusion: Adjuvant EGFR‐TKIs could significantly improve DFS among patients with stage IB lung adenocarcinoma compared with CO, with a safe and tolerable profile.

2 December 2022 in BMC Cancer
Verified
Journal Article
Open access
PDF file
JGJuntang Guo
Juntang Guo
LSLeilei Shen
Leilei Shen
ZRZhipeng Ren
Zhipeng Ren
YLYang Liu
Yang Liu
CLChaoyang Liang
Chaoyang Liang
Background: In traditional opinion, solid pulmonary nodule suspected lung cancer should be confirmed by pathology before the operation to exclude small cell lung cancer (SCLC), considering SCLC tends to be aggressive and surgical effect in the management of SCLC remains controversial. The aim of this study was to evaluate the survival result and risk factors of postoperative unsuspected SCLC. Methods: A total of 120 patients with postoperative unsuspected SCLC who were confirmed by pathology and referred to Chinese PLA General Hospital between 2000 and 2021 were retrospectively analyzed (surgery group). Additionally, 120 patients with limited-stage SCLC who underwent chemotherapy and radiotherapy in the same period were enrolled in the chemoradiotherapy group.. Kaplan–Meier method was used to estimate survival; the Log-Rank test was used to compare survival rates between different groups; a COX stepwise regression model was used for multivariate analysis. Results: Among 120 patients in the surgery group, 28 were with central type and other 92 with peripheral type. The median survival (OS) was 44.85 months, and the 5-year survival rate was 46%. The 5-year survival rates for stage I, II, and III were 52.1%, 45.4%, and 27.8%, respectively. The mean disease-free survival time (DFS) was 30.63 ± 4.38 months, and the 5-year DFS rate was 31.5%. In the chemoradiotherapy group, the mean OS was 21.4 ± 4.26 months, and the 5-year survival rate was 28.3%. The 5-year survival rates for clinical stage I, II, and III were 42.5%, 39.8%, and 20.5%, respectively. The mean progression-free survival (PFS) was 10.63 ± 3.6 months. In the surgery group, one-way ANOVA revealed that the gender, symptoms, smoking history, tumor location, and postoperative radiotherapy were not associated with OS (P ≥ 0.05), while age, surgical approach, surgical method, N stage, TNM stage, and vascular tumor thrombus were related to OS (P < 0.05). Multivariate analysis indicated that the N stage was associated with OS (HR = 1.86 P = 0.042). Conclusion: Surgery and adjuvant therapy were found to have encouraging outcomes in postoperative unsuspected SCLC. Patients with stage I, stage II and part of stage IIIA SCLC could benefit from surgery and the standard lobectomy, and systematic lymph node dissection, is also recommended for these patients.

1 July 2009
Verified
Journal Article
Closed access
JGJuntang Guo
Juntang Guo
LDLi-Hua Ding
Li-Hua Ding
CLChao-Yang Liang
Chao-Yang Liang
NZNai-Kang Zhou
Nai-Kang Zhou
QYQi-Nong Ye
Qi-Nong Ye

1 September 2010
Verified
Journal Article
Closed access
XTXiao-Dong Tian
Xiao-Dong Tian
NZNai-Kang Zhou
Nai-Kang Zhou
BLBo-Jun Li
Bo-Jun Li
CXCang-Song Xiao
Cang-Song Xiao
XLXi Liu
Xi Liu
CGChang-Qing Gao
Chang-Qing Gao